Wave Life Sciences Stock
Wave Life Sciences Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Paul Bolno
- Employees
- 317
- Market cap
- $617 M
- IPO
- 11/11/2015
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human…
Wave Life Sciences stock: price history
1D
-1.9%
1W
-9.5%
1M
-30.6%
6M
-58.2%
YTD
-81.6%
1Y
-60.2%
2Y
-79.0%
5Y
-39.2%
10Y
-89.1%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~2% stronger price swings than usual
Wave Life Sciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Ask the agents about Wave Life Sciences
Analyst assessment of Wave Life Sciences
PRICE TARGET LOW
US$11.00
CONSENSUS
US$13.17
MEDIAN
US$13.00
PRICE TARGET HIGH
US$15.00
1
STRONG BUY
22
BUY
2
HOLD
0
SELL
0
STRONG SELL
25
TOTAL · Buy
As of: 23/09/2026
Wave Life Sciences stock metrics
P/E
-2.87
P/B
1.39
EV/EBITDA
-1.48
RETURN ON EQUITY
-15.3%
NET MARGIN
-3,052.6%
DEBT/EQUITY
0.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.8%
FLOAT SHARES
165,171,151
AVG. DAILY VOLUME (30D)
3,193,217
Insider transactions (SEC)
RA CAPITAL MANAGEMENT, L.P.
Rawcliffe Adrian
CORRIGAN MARK
TAKANASHI KEN
Tan Aik Na
Institutional holders
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Wave Life Sciences stock
What does Wave Life Sciences do?
Wave Life Sciences Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Paul Bolno, the company employs around 317 people.
The IPO was on 11/11/2015; the stock trades on NASDAQ under the ticker WVE.
What do analysts say about Wave Life Sciences stock?
25 analysts rate the stock, the consensus is Buy (as of 23/09/2026).
The average price target is US$13.17, ranging from US$11.00 to US$15.00, with a median of US$13.00.
This is an external assessment, not a statement by Market Jury.
When does Wave Life Sciences report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 2% stronger than usual.
Does Wave Life Sciences pay a dividend?
No, Wave Life Sciences currently does not pay a dividend.
Which stocks are comparable to Wave Life Sciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Wave Life Sciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Wave Life Sciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.